What Differs Between Vitamin D2 and D3

Vitamin D is not a single compound. The umbrella term covers a family of fat-soluble secosteroids, and the two forms that appear most often in supplements and fortified foods are ergocalciferol (D2) and cholecalciferol (D3). Each arrives in the body through a different source, travels through the same activation pathway, and yet produces measurably different outcomes at the level of circulating blood metabolites.

The distinction matters because vitamin D's downstream roles — including its well-documented influence on calcium absorption in the gut — depend on how efficiently each form is converted to the active hormone and how long that conversion sustains a measurable effect. This piece maps the structural and metabolic differences between D2 and D3 without prescribing which form belongs in any supplement regimen.

How D2 and D3 Each Travel Through the Activation Pathway

Both D2 and D3 are biologically inert when they first enter circulation. Each must be hydroxylated twice before it can bind to the vitamin D receptor (VDR) and influence gene expression. The first hydroxylation step occurs in the liver, where the enzyme CYP2R1 converts either form to 25-hydroxyvitamin D — written as 25(OH)D2 or 25(OH)D3, respectively. This intermediate is the metabolite measured in standard serum tests and is used clinically as the primary indicator of vitamin D status.

The second hydroxylation happens primarily in the kidney, where CYP27B1 converts 25(OH)D to 1,25-dihydroxyvitamin D (calcitriol), the biologically active hormone. Calcitriol then binds the VDR, a nuclear receptor present in cells throughout the body, and modulates the transcription of hundreds of genes involved in mineral metabolism, immune signaling, and cell differentiation.

The critical difference between D2 and D3 emerges at the first hydroxylation step and in what happens after. Research published through the NIH Office of Dietary Supplements indicates that D3 raises serum 25(OH)D more efficiently than an equivalent amount of D2 and sustains that elevation for a longer period. The leading structural explanation involves the C17 side chain: D2 carries an additional double bond and a methyl group at C24, which appear to make its 25(OH)D2 metabolite less stable and more rapidly catabolized by the enzyme CYP24A1, the same enzyme that degrades active vitamin D once it is no longer needed.

In practical metabolic terms, D3 produces a higher and longer-lasting 25(OH)D response per unit ingested compared with D2, though the magnitude of that difference varies across studies and across individuals.

Compounds, Organs, and Binding Proteins Involved in Each Form

Ergocalciferol (D2) is derived from ultraviolet irradiation of ergosterol, a sterol found in fungi and yeast. This makes it the form most often used in plant-based or vegan-labeled supplements, since cholecalciferol is typically synthesized from lanolin, a byproduct of sheep's wool.

Cholecalciferol (D3) is the form the human skin synthesizes endogenously when UVB radiation (wavelengths 290–315 nm) strikes 7-dehydrocholesterol in the epidermis. The same form is also present in fatty fish, fish liver oils, and egg yolks. Because skin synthesis depends on UVB intensity, latitude, season, skin pigmentation, and age, endogenous production alone is unreliable in many populations.

The liver (CYP2R1 and CYP27A1) performs the first hydroxylation for both forms. The liver's handling of the two metabolites — 25(OH)D2 versus 25(OH)D3 — differs in binding affinity. Vitamin D-binding protein (VDBP), the primary transport protein in serum, binds 25(OH)D3 with approximately threefold greater affinity than 25(OH)D2. This difference in VDBP affinity is thought to contribute to the faster clearance of the D2 metabolite.

The kidney (CYP27B1) carries out the second hydroxylation to produce calcitriol from whichever 25(OH)D form is available. Both 25(OH)D2 and 25(OH)D3 are substrates for this enzyme, though the relative efficiency with which each is converted remains an area of ongoing research.

CYP24A1, present in the kidney and other tissues, is the catabolic enzyme that initiates degradation of both 25(OH)D and calcitriol. The additional methyl group at C24 in D2's side chain appears to alter the rate at which CYP24A1 degrades the D2 metabolite, contributing to its shorter half-life in serum.

The vitamin D receptor (VDR) is a nuclear receptor that binds calcitriol — the final active form derived from either D2 or D3 — with essentially equal affinity. Once bound, the VDR–calcitriol complex dimerizes with the retinoid X receptor (RXR) and regulates gene transcription. The receptor itself does not distinguish between calcitriol derived from D2 versus D3; the difference between the two parent forms is upstream, at the level of conversion and metabolite stability.

Where the D2-vs-D3 Distinction Breaks Down or Surprises

The most common misunderstanding is that D2 is simply "inferior" in all contexts. The reality is more conditional. At very high single doses, the difference in potency between D2 and D3 narrows in some study designs, suggesting that the gap in serum response is partly a function of dosing frequency rather than an absolute structural inferiority. Daily supplementation studies tend to show a clearer D3 advantage in sustaining 25(OH)D levels; studies using infrequent bolus doses show less consistent separation.

A second friction point involves the serum assay itself. Standard clinical tests measure total 25(OH)D, but many immunoassay platforms used in routine labs do not distinguish between 25(OH)D2 and 25(OH)D3. Liquid chromatography–tandem mass spectrometry (LC-MS/MS) separates the two metabolites, but it is not universally used. A person supplementing with D2 may receive a total 25(OH)D reading that appears similar to one produced by D3 supplementation, even though the metabolite composition and its durability differ.

A third area of unexpected results involves individual variation in VDBP genotype. Genetic polymorphisms in the GC gene, which encodes VDBP, alter the protein's binding affinity and serum concentration. Populations with lower VDBP concentrations or altered binding variants may process both D2 and D3 differently from the average response reported in clinical trials, making population-level comparisons less predictive for any individual.

Finally, the vitamin D formulation itself — whether oil-based, powder-in-capsule, or emulsified — affects absorption of either form before the conversion question even arises. Because both D2 and D3 are fat-soluble, their absorption from the small intestine depends on the presence of bile acids and dietary fat. A supplement delivered in a fat-free matrix may absorb less efficiently than one delivered in an oil carrier, regardless of which form of vitamin D it contains. This is a parallel dynamic to how water-soluble vitamins like vitamin C face entirely different absorption constraints, governed by transporter saturation rather than fat co-ingestion.

What a Supplement Label and Third-Party Certification Show for D2 and D3

A supplement facts panel is required by the FDA to list vitamin D in micrograms (mcg) with an IU equivalent in parentheses, and it must identify the form as either ergocalciferol (D2) or cholecalciferol (D3). This is one of the more informative disclosures on a dietary supplement label, because the form name is standardized and unambiguous. A label listing "Vitamin D (as Cholecalciferol)" and one listing "Vitamin D (as Ergocalciferol)" are making chemically distinct claims that can be verified analytically.

What the label does not show is the bioavailability of that declared amount under the specific formulation conditions — oil-based versus dry powder, emulsified versus non-emulsified. The declared amount reflects what was added during manufacturing, not what a given individual will absorb. No dietary supplement label is permitted to make FDA-approved bioavailability claims, because no dietary supplement undergoes FDA pre-market approval; under DSHEA, the manufacturer is responsible for safety and label accuracy before a product reaches market.

Third-party certification programs — such as those described in detail when comparing NSF certification and USP verification — test whether the declared amount of vitamin D is actually present in the finished product and whether the product is free from specified contaminants. These programs can confirm that a label claiming 25 mcg of cholecalciferol contains approximately that amount. They do not test for in-body conversion efficiency, individual absorption variation, or the relative potency of D2 versus D3 in any given person. A certificate of analysis or third-party seal attests to what is in the bottle, not to what the body will do with it.

For consumers reading labels, the practical takeaway from the regulatory record is that the form disclosure (D2 vs. D3) is reliable and enforceable, while the implied equivalence of equal IU amounts across forms is not — because IU equivalence was originally established using older bioassay methods that have since been called into question by more precise metabolite studies.

The structural gap between ergocalciferol and cholecalciferol is small — a single extra double bond and a methyl group — yet that small difference propagates through binding protein affinity, metabolite stability, and serum half-life in ways that produce a measurable divergence in how each form sustains circulating 25(OH)D. The chemistry is settled enough to be useful context; the clinical significance in any individual case is not fixed, and varies with formulation, dosing interval, genetics, and baseline status.

Note: This explains how supplements work. This statement has not been evaluated by the Food and Drug Administration. This information is not intended to diagnose, treat, cure, or prevent any disease, and it is not a substitute for advice from a physician, pharmacist, or registered dietitian.